- Launched first commercial product, AlloMap® Heart, in 2005, now used by over 90% of U.S. transplant centers
- Launched second surveillance product, AlloSure®, in 2017, using dd-cfDNA to determine graft injury
- Ushering in the next generation in transplant management by leading the shift to multi-modality testing with HeartCare®, HistoMap, and UroMap